Collegium Pharmaceutical, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Collegium Pharmaceutical, Inc. (COLL) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $44.78 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2021-11-04.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-11-04
- Collegium Pharmaceutical, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-03-31 was $44.78M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month |
|---|---|
| 2020-03-31 | $44.78M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |